Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G
Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02, Malmö, Sweden.
Br J Cancer. 2003 Nov 17;89(10):1920-6. doi: 10.1038/sj.bjc.6601398.
Ductal carcinoma in situ (DCIS) of the breast constitutes about 10% of all diagnosed breast cancers and, despite surgical removal, it may recur, either as DCIS or invasive breast cancer. Nuclear grade and growth pattern according to Andersen et al as well as surgical margins are factors that have been used to predict local recurrence, but ideally a set of tumour-specific factors should be identified and used as prognostic markers. Many cell cycle regulatory gene products have been shown to be involved in the formation of tumours and are either oncogenes or suppressor genes and involved in key processes in the transformation. We therefore characterised the cell cycle regulators cyclin E, cyclin D1, p27 and p16 in a material of DCIS cases arranged in a tissue microarray. With a manual tissue arrayer, 52% of the initial 177 DCIS samples were successfully targeted allowing immunohistochemical analyses of all four proteins in 92 cases of DCIS. As also observed in invasive breast cancer, there was a trend indicating that DCIS cases with high cyclin D1 were cyclin E low and oestrogen receptor-positive, whereas cyclin E high DCIS cases were cyclin D1 low and oestrogen receptor-negative. For the 64 patients that did not receive postoperative radiotherapy, there were 16 local recurrences (eight DCIS and eight invasive breast cancer) during a mean follow-up time of 63 months. Cyclin E, p27 or p16 were not associated with local recurrence, but interestingly cyclin D1 was significantly and inversely associated with local recurrence, both using univariate and multivariate analyses. In summary, using a tissue array approach we have shown that cyclin D1, besides growth pattern, is a prognostic marker for local recurrence in DCIS.
乳腺导管原位癌(DCIS)约占所有确诊乳腺癌的10%,尽管已手术切除,但仍可能复发,复发形式可为DCIS或浸润性乳腺癌。Andersen等人提出的核分级和生长模式以及手术切缘是用于预测局部复发的因素,但理想情况下,应确定一组肿瘤特异性因素并将其用作预后标志物。许多细胞周期调节基因产物已被证明参与肿瘤形成,它们要么是癌基因,要么是抑癌基因,参与细胞转化的关键过程。因此,我们在组织微阵列中排列的DCIS病例材料中对细胞周期调节因子细胞周期蛋白E、细胞周期蛋白D1、p27和p16进行了特征分析。使用手动组织阵列仪,最初177个DCIS样本中有52%被成功定位,从而能够对92例DCIS病例中的所有四种蛋白质进行免疫组织化学分析。正如在浸润性乳腺癌中也观察到的那样,有一种趋势表明,细胞周期蛋白D1高的DCIS病例细胞周期蛋白E低且雌激素受体阳性,而细胞周期蛋白E高的DCIS病例细胞周期蛋白D1低且雌激素受体阴性。对于64例未接受术后放疗的患者,在平均63个月的随访期内有16例局部复发(8例DCIS和8例浸润性乳腺癌)。细胞周期蛋白E、p27或p16与局部复发无关,但有趣的是,无论是单因素分析还是多因素分析,细胞周期蛋白D1均与局部复发显著负相关。总之,使用组织阵列方法我们已经表明,除生长模式外,细胞周期蛋白D1是DCIS局部复发的预后标志物。